Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
Pediatr Transplant
; 18(4): 350-6, 2014 Jun.
Article
in En
| MEDLINE
| ID: mdl-24802342
ABSTRACT
The three yr results of a multicenter trial in de novo pediatric KT treated with a proliferative signal inhibitor and low dose CNI are presented. Thirty-seven children (9.1 ± 5 yr old) received basiliximab, cyclosporine A (CyA C21400 ng/mL), (MMF C01.5-3 µg/mL), and prednisone. Three wk later everolimus was started (C05-10 ng/mL), CyA was reduced (C2600 ng/mL after 90 days 300 ng/mL), and MMF discontinued. During the three-yr period patient and graft survivals were 96%. One patient died for causes unrelated to the immunosuppression. Cumulative acute rejection rate including protocol and indication biopsies was 21.9%. None of the patients had signs of chronic humoral rejection. Incidence of dnDSA was 5%, 11%, and 22% at one, two, and three yr post-transplant, respectively. Mean glomerular filtration rate measured at one yr and three yr post-transplant was 105.5 ± 31 and 110.7 ± 27 mL/min/1.73 m(2), respectively. A growth velocity of 7.7 ± 6.7 cm/yr was achieved with positive catch-up growth. No malignancy or post-transplant lymphoproliferative diseases were diagnosed. In conclusion, the treatment based on basiliximab induction, everolimus, low-dose cyclosporine, and low-dose prednisone leads to good long-term efficacy in de novo pediatric KT recipients.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Cyclosporine
/
Sirolimus
/
Graft Rejection
/
Immunosuppressive Agents
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Language:
En
Year:
2014
Type:
Article